Reversing breast cancer stem cell into breast somatic stem cell

Current Pharmaceutical Biotechnology

Volumn 12, Issue 2, 2011, Pages 189-195

  Wijaya, L ^a   Agustina, D ^a   Lizandi, A O ^a   Kartawinata, M M ^a   Sandra, F ^a  

^a Stem Cell and Cancer Institute   (Indonesia)

Author keywords

Breast cancer stem cell; Breast somatic stem cell; Differentiation therapy; Stem cell niche

Indexed keywords

BETA1 INTEGRIN; CD133 ANTIGEN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; HERMES ANTIGEN; STEM CELL ANTIGEN 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; EMBRYONIC STEM CELL; HUMAN; INTRADUCTAL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; SOMATIC CELL;

EID: 79551649402     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794295819     Document Type: Article

References (58)

1. Klonisch, T.; Wiechec, E.; Klonisch, S. H.; Ande, S. R.; Wesselborg, S. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med., 2008, 14(10) (doi,10.1016/ j.molmed.2008.08.003).
2. Campbell, L.L.; Polyak, K. Breast tumor heterogeneity. Cell Cycle, 2007, 6(19), 2332-2338.
3. Postovit, L.M.; Margaryan N.V.; Seftor, E.A.; Kirschmann, D.A.; Lipavsky, A. Human embryonic stem cell microenvironment suppress the tumorigenic phenotype of aggressive cancer cells. Proc. Natl. Acad. Sci. USA, 2008, 105(11), 4329-4334.
4. Pierce, G. B.; Pantazis, C. G.; Caldwell, J. E.; Wells, R. S. Specificity of the control of tumour formation by the blastocyst. Cancer Res., 1982, 42(3), 1082-1087.
5. Villadsen, R.; Fridriksdottir, A. J.; Rønnov-Jessen, L. Evidence for a stem cell hierarchy in the adult human breast. J. Cell. Biol., 2007, 177(1), 87-101.
6. Morrison, B. J.; Schmidt, C. W.; Lakhani, S. R.; Reynolds, B. A.; Lopez, J. A. Breast cancer stem cells, implications for therapy of breast cancer. Breast Cancer Res., 2008, 10, 210.
7. Liu, S.; Dontu, G.; Wicha, M. S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res., 2005, 7(3), 86-95.
8. Cocola, C.; Sanzone, S.; Astigiano, S. A rat mammary gland cancer cell with stem cell properties of self-renewal and multi-lineage differentiation. Cytotechnology, 2008, 58, 25-32.
9. Ruiz-Vela, A.; Aguilar-Gallardo, C.; Simon C. Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Rev. Rep., 2009, 5(4), 319-327.
10. Dontu, G.; Liu, S.; Wicha, M. S. Stem cells in mammary development and carcinogenesis, implications for prevention and treatment. Stem Cell Rev. Rep., 2005, 1(3), 207-213.
11. Verslues, W. W. H.; Chang, K. J.; Lee, E. Y.; Lee, W. H. Breast cancer stem cells and tumor suppressor genes. J. Formos. Med. Assoc., 2008, 107(10), 751-766.
12. Hiyama, E.; Hiyama, K. Telomere and telomerase in stem cells. Br. J. Cancer, 2007, 96, 1020-1024.
13. Brabletz, T.; Jung, A.; Spaderna, S.; Hlubek, F.; Kirchner, T. Opinion, migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer, 2005, 5, 744-749.
14. Brown, M. D. Characterization of benign and malignant prostate epithelial Hoechst 33342 site population. Prostate, 2007, 67, 1384-1396.
15. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev., 2003, 17, 1253-1270.
16. Shackleton, M.; Vaillant, F.; Simpson, K. J. Generation of a functional mammary gland from a single stem cell. Nature, 2006, 439, 993-997.
17. Richardson, G. D.; Robson, C. N.; Lang, S. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. USA, 2004, 117, 3539-3545.
18. Ouhtit, A.; Elmageed, Z.Y. A.; Abdraboh, M.E. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am. J. Pathol., 2007, 171, 2033-2039.
19. LaBarge, M. A.; Nelson, C. M.; Villadsen, R.; Fridriksdottir, A.; Ruth, J. R. Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. Integr. Biol., 2009, 1, 70-79.
20. LaBarge, M. A.; Petersen, O. W.; Bissell, M. J. Of microenvironments and mammary stem cells. Stem Cell Rev., 2007, 3(2),137-146.
21. Wicha, M. S.; Liu, S.; Dontu, G. Cancer stem cells, an old idea-a paradigm shift. Cancer Res., 2006, 66(4), 1883-1890.
22. Brisken, C.; Duss, S. Stem cells and the stem cell niche in the breast, an integrated hormonal and developmental perspective. Stem Cell Rev. Rep., 2007, 3(2), 147-156.
23. Farnie, G.; Clarke, R. B.; Spence, K.; Pinnock, N.; Brennan, K. Novel cell culture technique for primary ductal carcinoma in situ, role of notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst., 2007, 99(8), 616-627.
24. Polyak, K. Breast cancer, origins and evolution. 2007, J. Clin. Invest., 117(11), 3155-3163.
25. Wulfkuhle, J. D.; Sgroi, D. C.; Krutzch, H.; McLean, K.; McGarvey, K. Proteomics of human breast ductal carinoma in situ. Cancer Res., 62, 2002, 6740-6749.
26. Lynch, M.D.; Cariati, M.; Purushotham, A.D. Breast cancer, stem cells and prospects for therapy. Breast Cancer Res., 2006, 8, 211.
27. Polakis, P. Wnt signaling and cancer. Genes Dev., 2000, 14, 1837-1851.
28. Moon, R.T.; Bowerman, B.; Boutros, M.; Perrimon, N. The promise and perils of Wnt signaling through beta-catenin. Science, 2002, 296, 1644-1646.
29. Klopocki, E.; Kristiansen, G.; Wild, P.J.; Klaman, I.; Castanos-Velez, E. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumours. Int. J. Oncol., 2004, 25, 641-649.
30. Ugolini, F.; Charafe-Jauffret, E.; Bardou, V.J.; Geneix, J.; Adelaide, J. WNT pathway and mammary carcinogenesis, loss of expression of candidate tumour suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene, 2001, 20, 5810-5817.
31. Tepera, S. B.; McCrea, P. D.; Rosen, J. M. A beta-catenin survival signal is required for normal lobular development in the mammary gland. J. Cell. Sci., 2003, 116,1137-1149.
32. Li, Y.; Welm, B.; Podsypanina, K.; Huang, S.; Chamorro, M. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 15853-15858.
33. Liu, B. Y.; McDermott, S. P.; Khwaja, S. S.; Alexander, C. M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl. Acad. Sci. USA, 2004, 101, 4158-4163.
34. Brennan, K.; Brown, A. M. C. Is there a role for Notch signalling in human breast cancer? Breast Cancer Res., 2003, 5, 69-75.
35. Soriano, J. V.; Uyttendaele, H.; Kitajewski, J.; Montesano, R. Expression of an activated Notch4 (int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int. J. Cancer, 2000, 86, 652-659.
36. Behbod, F.; Rosen, J.M. Will cancer stem cells provide new therapeutic targets? Carcinogenesis, 2005, 26, 703-711.
37. Dontu, G.; Jackson, K.W.; McNicholas, E.; Kawamura, M.J.; Abdallah, W.M.; Wicha, M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res., 2004, 6, R605-R615.
38. Magliano, M. P.; Hebrok, M. Hedgehog signaling in cancer formation and maintenance. Nat. Rev. Cancer, 2003, 3, 903-911.
39. Berman, D. M.; Karhadkar, S. S.; Maitra, A.; Montes De Oca, R.; Gerstenblith, M. R. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature, 2003, 425, 846-851.
40. Lee, S. W.; Moskowitz, M. A.; Sims, J. R. Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. Int. J. Mol. Med., 2007, 19(3), 445-451.
41. Adolphe, C.; Hetherington, R.; Ellis, T.; Wainwright, B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res., 2006, 66(4), 2081-2088.
42. Athar, M.; Li, C.; Tang, X.; Chi, S.; Zhang, X.; Kim, A. L. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res., 2004, 64(20), 7545-7552.
43. Kubo, M.; Nakamura, M.; Tasaki, A.; Yamanaka, N.; Nakashima, H. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res., 2004, 64, 6071-6074.
44. Lewis, M. T.; Ross, S.; Strickland, P. A.; Sugnet, C. W.; Jimenez, E. Defects in mouse mammary gland development caused by conditional haploinsufficiency of Patched-1. Development, 1999, 126, 5181-5193.
45. Hui, C.; Daniel, C. W. The Gli2 transcription factor is required for normal mouse mammary gland development. Dev. Biol., 2001, 238, 133-144.
46. Wobus, A. M.; Boheler K. R. Embryonic stem cells, prospects for developmental biology and cell therapy. Physiol. Rev., 2005, 85, 635-678.
47. Tang, B.; Yoo, N.; Vu, M.; Mamura, M.; Nam, J. S. Transforming growth factor-ß can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res., 2007, 67(18), 8643-8652.
48. Durr, M.; Harder, F.; Merkel, A. Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts. Oncogene, 2003, 22(57), 9185-9191.
49. Hendrix, M. J.; Seftor, E. A.; Seftor, R. E. Reprogramming metastatic tumor cells with embryonic microenvironments. Nat. Rev. Cancer, 2007, 7(4), 246-255.
50. Gunther, E. J.; Moody, S. E.; Belka, G. K.; Hahn, K. T.; Innocent, N. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev., 2003, 17, 488-501.
51. Li, W.; Ding, S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol. Sci., 2010, 31, 36-45.
52. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126, 663-676.
53. Biava, P. M.; Bonsignorio, D.; Hoxa, M. Cell proliferation curves of different human tumor lines after in vitro treatment with Zebrafish embryonic extracts. J. Tumor Marker Oncol., 2001, 16, 195-202.
54. Biava, P. M.; Carluccio, A. Activation of anti-oncogene p53 produced by embryonic extracts in vitro tumor cells. J. Tumor Marker Oncol., 1977, 12, 9-15.
55. Biava, P. M.; Bonsignorio, D.; Hoxa, M.; Facco, R.; Ielapi, T.; Frati, L.; Bizzarri, M. Post-traslational modification of the retinoblastoma protein (pRb) induced by in vitro administration of Zebrafish embryonic extracts on human kidney adenocarcinomacell line. J. Tumor Marker Oncol., 2002, 17(2), 59-64.
56. Cucina, A.; Biava, P. M.; D'Anselmi, F.; Coluccia, P.; Conti, F.; Di Clemente, R.; Miccheli, A.; Frati, L.; Gulino, A.; Bizzarri, M. Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). Apoptosis, 2006, 9, 1617-1628.
57. Biava, P. M.; Bonsignorio, D. Cancer and cell differentiation, a model to explain malignancy. J. Tumor Marker Oncol., 2002, 17(3), 47-54.
58. Livraghi, T.; Meloni, F.; Frosi, A.; Lazzaroni, S.; Bizzarri, M.; Frati, L.; Biava, P.M. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma, an open randomized clinical trial. Oncol. Res., 2005, 15(7,8), 399-408.